134 related articles for article (PubMed ID: 35098372)
21. A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes.
Hals IK; Balasuriya C; Casas R; Ludvigsson J; Björklund A; Grill V
Diabetes Obes Metab; 2023 Nov; 25(11):3400-3409. PubMed ID: 37580967
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.
Chéramy M; Hampe CS; Ludvigsson J; Casas R
Clin Exp Immunol; 2013 Mar; 171(3):247-54. PubMed ID: 23379430
[TBL] [Abstract][Full Text] [Related]
23. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
Axelsson S; Hjorth M; Akerman L; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
[TBL] [Abstract][Full Text] [Related]
24. Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of glutamic acid decarboxylase (GAD)-alum immunotherapy in recent-onset type 1 diabetes.
Nowak C; Hannelius U; Ludvigsson J
Diabetes Obes Metab; 2022 Aug; 24(8):1647-1655. PubMed ID: 35434906
[No Abstract] [Full Text] [Related]
25. Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial.
Ludvigsson J; Sumnik Z; Pelikanova T; Nattero Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Katsarou A; Hanas R; Hernandez C; Clemente León M; Gómez-Gila A; Lind M; Lozano MF; Sas T; Samuelsson U; Pruhova S; Dietrich F; Puente Marin S; Nordlund A; Hannelius U; Casas R
Diabetes Care; 2021 Jul; 44(7):1604-1612. PubMed ID: 34021020
[TBL] [Abstract][Full Text] [Related]
26. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes.
Agardh CD; Lynch KF; Palmér M; Link K; Lernmark A
Diabetologia; 2009 Jul; 52(7):1363-8. PubMed ID: 19404608
[TBL] [Abstract][Full Text] [Related]
27. Glutamic acid decarboxylase immunotherapy for type 1 diabetes.
Ludvigsson J
Curr Opin Endocrinol Diabetes Obes; 2022 Aug; 29(4):361-369. PubMed ID: 35776501
[TBL] [Abstract][Full Text] [Related]
28. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes.
Boettler T; Pagni PP; Jaffe R; Cheng Y; Zerhouni P; von Herrath M
J Autoimmun; 2013 Aug; 44():40-8. PubMed ID: 23770292
[TBL] [Abstract][Full Text] [Related]
29. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
Hjorth M; Axelsson S; Rydén A; Faresjö M; Ludvigsson J; Casas R
Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
[TBL] [Abstract][Full Text] [Related]
30. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
Axelsson S; Chéramy M; Hjorth M; Pihl M; Akerman L; Martinuzzi E; Mallone R; Ludvigsson J; Casas R
PLoS One; 2011; 6(12):e29008. PubMed ID: 22174945
[TBL] [Abstract][Full Text] [Related]
31. Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes.
Barcenilla H; Pihl M; Wahlberg J; Ludvigsson J; Casas R
Front Immunol; 2021; 12():797172. PubMed ID: 35095874
[TBL] [Abstract][Full Text] [Related]
32. GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.
Arif S; Gomez-Tourino I; Kamra Y; Pujol-Autonell I; Hanton E; Tree T; Melandri D; Hull C; Wherrett DK; Beam C; Roep BO; Lorenc A; Peakman M
Diabetologia; 2020 Jun; 63(6):1186-1198. PubMed ID: 32248243
[TBL] [Abstract][Full Text] [Related]
33. Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12.
Achenbach P; Hawa MI; Krause S; Lampasona V; Jerram ST; Williams AJK; Bonifacio E; Ziegler AG; Leslie RD;
Diabetologia; 2018 Jul; 61(7):1644-1649. PubMed ID: 29619531
[TBL] [Abstract][Full Text] [Related]
34. Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial.
Ludvigsson J; Routray I; Elluru S; Leanderson P; Larsson HE; Rathsman B; Hanås R; Carlsson A; Ek T; Samuelsson U; Torbjörnsdotter T; Åman J; Örtqvist E; Badwal K; Beam C; Casas R
Future Sci OA; 2020 Jun; 6(7):FSO604. PubMed ID: 32802401
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes.
Hannelius U; Beam CA; Ludvigsson J
Diabetologia; 2020 Oct; 63(10):2177-2181. PubMed ID: 32754804
[TBL] [Abstract][Full Text] [Related]
36. Immune responses to glutamic acid decarboxylase and insulin in patients with gestational diabetes.
Füchtenbusch M; Bonifacio E; Lampasona V; Knopff A; Ziegler AG
Clin Exp Immunol; 2004 Feb; 135(2):318-21. PubMed ID: 14738462
[TBL] [Abstract][Full Text] [Related]
37. GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients.
Pihl M; Barcenilla H; Axelsson S; Chéramy M; Åkerman L; Johansson I; Ludvigsson J; Casas R
Clin Immunol; 2017 Mar; 176():114-121. PubMed ID: 28131926
[TBL] [Abstract][Full Text] [Related]
38. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77.
Desai M; Cull CA; Horton VA; Christie MR; Bonifacio E; Lampasona V; Bingley PJ; Levy JC; Mackay IR; Zimmet P; Holman RR; Clark A
Diabetologia; 2007 Oct; 50(10):2052-60. PubMed ID: 17657474
[TBL] [Abstract][Full Text] [Related]
39. GAD65: a prospective vaccine for treating Type 1 diabetes?
Ludvigsson J
Expert Opin Biol Ther; 2017 Aug; 17(8):1033-1043. PubMed ID: 28480759
[TBL] [Abstract][Full Text] [Related]
40. Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route.
Ludvigsson J
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
